Britain and America have forged a important bilateral deal that will preserve zero import taxes on British drug shipments going into the American market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has committed to increase funding on pharmaceuticals through the public health system. This pledge secures that duties on these vital exports will stay at nothing for a duration of three years.
This agreement follows previous warnings to hike tariffs on branded drug products, with increases floated as high as 100%.
"This agreement between the Britain reinforces the global environment for cutting-edge drugs and introduces long-overdue balance to American-British pharmaceutical trade," a statement noted.
Trade Impact
Pharmaceuticals are one of the UK's most significant export categories to the United States, which is clearly the largest destination for large UK drugmakers.
Trade data reveal that in the year prior to last September, the UK shipped drugs worth over eleven billion pounds to the US. This amount accounted for nearly one-fifth of all goods exports in that span.
"This deal safeguards jobs, stimulates investment and facilitates the UK to emerge as a global hub for medical research," a minister remarked.
Detailed British Pledges
The deal includes several specific commitments from the UK:
- Higher Cost Ceiling: The UK will raise the price threshold at which it deems new treatments to be too expensive by 25%.
- Boosted Medicine Funding: There is a target to double total health service expenditure on medicines from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The percentage manufacturers must return to the NHS to control costs will be restricted at fifteen percent. In the past, refunds topped 20%.
Industry Background
The pact comes amid a long-running dispute between the pharmaceutical industry and the British authorities over drug pricing and approval rates.
The disagreement were intensified by claims that American customers were charged several times more for the equivalent treatments than consumers in the UK and Europe.
Over the last 18 months, several large manufacturing plans in the UK have been halted or cancelled, while substantial expansions have been pledged toward US facilities.
A senior figure stated that the NHS must invest a greater share on treatments, noting that its expenditure on drugs had shrunk as a proportion of its overall budget over the last ten years.
